CClinicalTrials.gg
RecruitingNCT04185935Updated Jun 29, 2026

Molecular Genetics Studies of Cancer Patients and Their Relatives

An observational study in Malignant Neoplasm, sponsored by City of Hope Medical Center. Recruiting at 42 sites in 5 countries. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by City of Hope Medical Center · Observational

From the registry’s dates

  • Started Apr 1997; still recruiting 29 years 5 months later.
Study type
Observational
Model
Family-based
Time perspective
Prospective
Enrollment
999,999
Sex
All
01

Study summary

This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.

Read the detailed description

PRIMARY OBJECTIVES:

I. To identify rare cancer patients and families in whom the pattern of disease suggests a genetic susceptibility to cancer or other etiology suggestive of a carcinogenic exposure and to characterize the underlying predisposition.

II. To determine the contribution of heredity (genotype) and biomarkers to clinical outcome (phenotype, occurrence of new cancers, prognosis and quality of life) in subgroups of cancer patients with and without clinical high-risk features.

OUTLINE:

Patients may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.

02

Conditions studied

  • Malignant Neoplasm

Browse trials for

03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's planned enrollment of 999,999 is above the median of 204 across 1,683 observational studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

City of Hope Medical Center is the lead sponsor of 670 studies on the registry; 181 are open to participants now.

Of its 30 completed or terminated interventional studies of FDA-regulated products, 12 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Participants with a family history of cancer

Inclusion criteria

  • Individuals must have a personal history of cancer and/or a family history of cancer suggestive of the presence of an inherited predisposition. This inherited predisposition might manifest as:

    • Young age cancer diagnosis
    • Multiple primary neoplasms in affected member
    • The presence of rare tumor types in the family
    • Congenital malformations
    • Any other family clustering of cancer
    • Any other cancer-predisposing genetic diseases/conditions
  • Individuals may also be eligible by participation in the City of Hope Cancer Screening \& Prevention Program Network (CSPPN) clinical service or on the basis of membership in a group known or suspected to have an increased risk of carrying a genetic alteration or of sustaining a particular exposure that would place that at increased risk of cancer. (Examples would include members of occupational cohorts like asbestos workers, individuals with multiple dysplastic nevi in the absence of a family history of cancer, and individuals descended from a particular tribe in the American Southwest who have an increased incidence of a rare genetic alteration associated with an increased risk of a specific cancer.)
  • Individuals and families may be referred to us in a number of different ways. After initial contact is made with a individual or family by family studies personnel; an individual within the bloodline will be identified as the historian. There may be more than one historian within a family
  • At least one historian must be wiling to provide information or access as needed to contact appropriate family members for documentation of cancer and for consent. An individual is considered to be eligible to participate if they criteria; contact with relatives is not always indicated
  • Individuals who are under 18 are eligible for study if they meet the criteria. Consent for participation must be given by a legal guardian or parent
  • Deceased patients may be included in the study. Public records, such as death certificates, can be used to confirm information from individuals or family members. If medical records are needed, consent for these records will be obtained from the deceased's next of kin. Next of kin refers to the following hierarchy of relatives; spouse, offspring, parents, and siblings. (Any further use of next of kin in this protocol should relate back to this hierarchy.) Archived tissue samples, such as pathology blocks or snap frozen tumor from a pathology department tumor bank (discard specimens) may be used for genetic research

Exclusion criteria

Exclusion Criteria:

  • A family may be ineligible for study if the historian will not allow access to anyone within the family and thus, the accuracy of the family history cannot be established
05

Study design

Observational model
Family-based
Time perspective
Prospective
Enrollment
999,999 participants (estimated)
Biospecimen retention
Samples with dna

Groups and cohorts

  • Ancillary-correlative (biospecimen collection)

    Participants may provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue.

    Other: Biospecimen Collection · Other: Questionnaire Administration

Interventions

  • OtherBiospecimen Collection

    Provide a sample of blood, a saliva sample, a sample of eyebrow plucks, a sample of urine, and/or stored tumor or healthy tissue

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Cancer risk assessment

    Time frame: Up to 10 years

  2. Exploratory biomarkers for future studies

    Time frame: Up to 10 years

07

Study locations

41 of 42 sites recruiting
  • Valleywise Comprehensive Health Center - Phoenix
    Phoenix, Arizona 85008, United States
    Recruiting
  • John Muir Medical Center-Concord Campus
    Concord, California 94520, United States
    Recruiting
  • City of Hope Medical Center
    Duarte, California 91010, United States
    • Jeffrey N. Weitzel · Contact · jweitzel@coh.org · 626-218-4334
    • Jeffrey N. Weitzel · Principal investigator
    Recruiting
  • Saint Jude Medical Center
    Fullerton, California 92835, United States
    Recruiting
  • Saddleback Memorial Medical Center
    Laguna Hills, California 92653, United States
    • Jeffrey N. Weitzel · Contact · jweitzel@coh.org · 626-218-4334
    • Jeffrey N. Weitzel · Principal investigator
    Recruiting
  • USC / Norris Comprehensive Cancer Center
    Los Angeles, California 90033, United States
    Recruiting
  • Saint Joseph Hospital - Orange
    Orange, California 92868, United States
    • Jeffrey N. Weitzel · Contact · jweitzel@coh.org · 626-218-4334
    • Jeffrey N. Weitzel · Principal investigator
    Recruiting
  • Sutter Cancer Centers Radiation Oncology Services-Roseville
    Roseville, California 95661, United States
    • Kristie A. Bobolis · Contact · bobolis@surewest.net · 916-782-5106
    • Kristie A. Bobolis · Principal investigator
    Recruiting
  • Cancer Center of Santa Barbara
    Santa Barbara, California 93105, United States
    • Frederic C. Kass · Contact · fkass@ccsb.org · 805-563-5854
    • Frederic C. Kass · Principal investigator
    Recruiting
  • Lynn Regional Cancer Center - West
    Boca Raton, Florida 33428, United States
    • Louise E. Morrell · Contact · LMorrell@brrh.com · 561-955-2141
    • Louise E. Morrell · Principal investigator
    Recruiting
  • Holy Cross Hospital
    Fort Lauderdale, Florida 33308, United States
    Recruiting
  • Kootenai Cancer Center
    Post Falls, Idaho 83854, United States
    • Jeffrey W. Allen · Contact · Mhander@kh.org · 208-625-4728
    • Jeffrey W. Allen · Principal investigator
    Recruiting
  • John H Stroger Jr Hospital of Cook County
    Chicago, Illinois 60612, United States
    Recruiting
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    • Lydia Usha · Contact · Lydia_Usha@rush.edu · 312-563-2200
    • Lydia Usha · Principal investigator
    Recruiting
  • Mercy Hospital
    Cedar Rapids, Iowa 52403, United States
    Recruiting
  • Suburban Hospital
    Bethesda, Maryland 20814, United States
    Recruiting
  • Frederick Oncology Hematology Associates
    Frederick, Maryland 21702, United States
    • Patricia A. Rice · Contact · price@fmh.org · 301-418-5010
    • Patricia A. Rice · Principal investigator
    Recruiting
  • Steward Saint Elizabeth's Medical Center
    Brighton, Massachusetts 02135, United States
    Recruiting
  • Hunterdon Medical Center
    Flemington, New Jersey 08822, United States
    • Kenneth B. Blankstein · Contact · kblankstein@hhpnj.org · 908-788-2566
    • Kenneth B. Blankstein · Principal investigator
    Recruiting
  • Lovelace Medical Center-Downtown
    Albuquerque, New Mexico 87102, United States
    Recruiting
  • New Mexico Oncology Hematology Consultants
    Albuquerque, New Mexico 87109, United States
    • Annette C. Fontaine · Contact · afontaine@nmohc.com · 505-480-1462
    • Annette C. Fontaine · Principal investigator
    Recruiting
  • Presbyterian Kaseman Hospital
    Albuquerque, New Mexico 87110, United States
    • Kenneth J. Smith · Contact · 505-559-6143
    • Kenneth J. Smith · Principal investigator
    Recruiting
  • Mount Kisco Medical Group at Northern Westchester Hospital
    Mount Kisco, New York 10549-3417, United States
    • Nancy Cohen · Contact · NCohen@nwhc.net · 914-242-7649
    • Nancy Cohen · Principal investigator
    Recruiting
  • Health Quest Medical Practice PC-Cardio Thoracic
    Poughkeepsie, New York 12601, United States
    Recruiting
  • Aultman Health Foundation
    Canton, Ohio 44710, United States
    Recruiting
  • Saint Charles Health System
    Bend, Oregon 97701, United States
    Recruiting
  • Paoli Memorial Hospital
    Paoli, Pennsylvania 19301, United States
    • Michael B. Dabrow · Contact · DabrowM@MLHS.ORG
    • Michael B. Dabrow · Principal investigator
    Recruiting
  • Reading Hospital
    West Reading, Pennsylvania 19611, United States
    Recruiting
  • The Don and Sybil Harrington Cancer Center
    Amarillo, Texas 79106, United States
    Recruiting
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
    Houston, Texas 77030, United States
    • April D. Sorrell · Contact · 713-798-6970
    • April D. Sorrell · Principal investigator
    Not yet recruiting
  • Doctor's Hospital of Laredo
    Laredo, Texas 78041, United States
    Recruiting
  • Covenant Medical Center
    Lubbock, Texas 79410, United States
    • Isaac Tafur · Contact · oncmd98@yahoo.com · 806-725-7993
    • Isaac Tafur · Principal investigator
    Recruiting
  • Saint Agnes Hospital/Agnesian Cancer Center
    Fond du Lac, Wisconsin 54935, United States
    • Michael W. Jones · Contact · 920-926-4100
    • Michael W. Jones · Principal investigator
    Recruiting
  • ProHealth Waukesha Memorial Hospital
    Waukesha, Wisconsin 53188, United States
    • Christopher R. Hake · Contact · chakemd@gmail.com · 262-928-5539
    • Christopher R. Hake · Principal investigator
    Recruiting
  • Cheyenne Regional Medical Center-West
    Cheyenne, Wyoming 82001, United States
    Recruiting
  • Clinica del Country
    Bogotá, Cundinamarca, Colombia
    Recruiting
  • Instituto de Cancerologia Las Americas
    Medellín, Colombia
    • Alicia M. Cock-Rada · Contact · alicia@oncogenetica.co · 574 3409393
    • Alicia M. Cock-Rada · Principal investigator
    Recruiting
  • University of Guadalajara
    Guadalajara, Jalisco CP 44340, Mexico
    • Adrian Daneri-Navarro · Contact · Daneri@cucs.udg.mx · 33 10585261
    • Adrian Daneri-Navarro · Principal investigator
    Recruiting
  • Salvador Zubiran National Institute of Health Sciences and Nutrition
    Mexico City, Tlalpan 14080, Mexico
    Recruiting
  • Monterrey Institute of Technology-TecSalud
    Nuevo León, Mexico
    • Cynthia Villarreal-Garza · Contact · cynthiavg@gmail.com · 528183898395
    • Cynthia Villarreal-Garza · Principal investigator
    Recruiting
  • Instituto Nacional de Enfermedades Neoplasicas
    Lima, Lima 34, Peru
    • Julio E. Abugattas Saba · Contact · jabugattas@inen.sld.pe · 51993579810
    • Julio E. Abugattas Saba · Principal investigator
    Recruiting
  • University of Puerto Rico
    San Juan, 00936, Puerto Rico
    • Marcia R. Cruz-Correa · Contact · marcia.cruz1@upr.edu · 787-772-8300
    • Marcia R. Cruz-Correa · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04185935
Lead sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Dec 4, 2019
Start date
Apr 18, 1997
Primary completion
Aug 18, 2033 (estimated)
Completion
Aug 18, 2033 (estimated)
Last update
Jun 29, 2026

Study contacts

Stephen Gruber
Contact
sgruber@coh.org
Stephen Gruber, MD
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion